ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CLL Cello Health Plc

161.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cello Health Plc LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 161.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Cello Group plc Directorate Change (2642M)

12/10/2016 7:00am

UK Regulatory


Cello Health (LSE:CLL)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Cello Health Charts.

TIDMCLL

RNS Number : 2642M

Cello Group plc

12 October 2016

Cello Group plc

Director appointment

Cello Group plc (AIM: CLL; "Cello", "The Group"), the healthcare focused strategic marketing group, is pleased to announce the appointment of Chris Jones as Non-Executive Director, effective as of October 17(th) 2016.

After graduating from Cambridge University, Chris spent 24 years in the advertising industry, ultimately becoming the Global Chairman and Chief Executive Officer of J Walter Thompson Co based in New York, part of WPP Group plc. Since moving back to England in 2002, Chris has held senior positions at companies in the healthcare, financial services, not-for-profit and technology industries. These include Board positions at the large quoted US clinical devices business Becton Dickinson and Co, Xenogen Inc, Freedom Holdings, Richmond Group, and Commarco.

Mark Scott, Chief Executive, commented: "We are delighted to have Chris onboard. He brings with him first-hand experience of growing global professional service businesses, as well as a deep knowledge of the healthcare sector in the US. His participation will be very helpful as we seek to expand Cello's footprint in the US as part of a more ambitious growth path. "

Other than that set out below, there are no other matters that are required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules in relation to the appointment of Chris Jones.

Current and previous directorships:

 
 Current directorships   Directorships within 
                          the last five years 
 Becton Dickinson &      Richmond Group 
  Co 
 Results International   Freedom Holdings 
  LLP 
 
 

12 October 2016

Enquiries:

 
 Cello Group                       020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Finance Director 
 
 Cenkos Securities                 0207 397 8900 
 Bobbie Hilliam 
  Harry Pardoe 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAFFLFLFFMSEDS

(END) Dow Jones Newswires

October 12, 2016 02:00 ET (06:00 GMT)

1 Year Cello Health Chart

1 Year Cello Health Chart

1 Month Cello Health Chart

1 Month Cello Health Chart

Your Recent History

Delayed Upgrade Clock